𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer

✍ Scribed by Angeles Alvarez Secord; Laura J. Havrilesky; Michael E. Carney; John T. Soper; Daniel L. Clarke-Pearson; Gustavo C. Rodriguez; Andrew Berchuck

Publisher
Springer
Year
2007
Tongue
English
Weight
210 KB
Volume
12
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized phase 2 study of concomitant
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer
✍ Robert Haddad; Stephen Sonis; Marshall Posner; Lori Wirth; Rosemary Costello; Pa πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 272 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: A randomized phase 2 study was performed to investigate the efficacy/toxicity of combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ##

Phase I trial of paclitaxel, carboplatin
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 3 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that